Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for atherosclerosis in rheumatoid arthritis
NCT04350216Phase 4Unknown
- Sponsor
- IDIVAL
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of sarilumab in atherosclerosis, sponsored by IDIVAL. Primary endpoints: Effect of Sarilumab on carotid atheroma plaque (effect on the inflammatory component) using ultrasound in patients with RA at 6 months and Effect of Sarilumab on carotid atheroma plaque (effect on the mineralization) using ultrasound in patients with RA at 6 months. Status: unknown.
02
Drugs
sarilumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT04350216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350216.